Septerna (SEPN) Net Income towards Common Stockholders (2023 - 2026)
Septerna's (SEPN) quarterly Net Income towards Common Stockholders came in at -$8.6 million in Q1 2026, up 59.78% year-on-year from -$5.4 million in Q1 2025, and up 19.57% quarter-over-quarter from -$10.7 million in Q4 2025.
Septerna (SEPN) Net Income towards Common Stockholders (2023 - 2026) Analysis & Trends
Septerna's Net Income towards Common Stockholders history runs 4 years deep, the most recent figure standing at -$8.6 million for Q1 2026.
- On a quarterly basis, Net Income towards Common Stockholders rose 59.78% year-over-year to -$8.6 million in Q1 2026; TTM through Mar 2026 was -$36.0 million, a 54.57% increase from a year earlier, with the FY2025 full-year figure at -$48.9 million, up 31.92% from the prior year.
- Net Income towards Common Stockholders grew to -$8.6 million in Q1 2026 per SEPN's latest filing, from -$10.7 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at $8.2 million in Q3 2025 and bottomed at -$24.8 million in Q2 2025.
- The 4-year median for Net Income towards Common Stockholders is -$16.7 million (2024), against an average of -$14.4 million.
- Across the five-year window, Net Income towards Common Stockholders sank 87.51% in 2024 and surged 139.82% in 2025, its largest moves.
- Year by year, Net Income towards Common Stockholders stood at -$18.2 million in 2023, then slipped by 13.85% to -$20.7 million in 2024, then jumped by 48.05% to -$10.7 million in 2025, then rose by 19.57% to -$8.6 million in 2026.
- Per Business Quant, the three latest SEPN Net Income towards Common Stockholders figures stand at -$8.6 million (Q1 2026), -$10.7 million (Q4 2025), and $8.2 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | -625.73 |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | -0.68 |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 472.00 Mn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | -453.82 Mn |
| 10 | Septerna | 1.51 Bn | 1.51 Bn | - | -8.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -8.64 Mn |
| Dec 31, 2025 | -10.74 Mn |
| Sep 30, 2025 | 8.17 Mn |
| Jun 30, 2025 | -24.84 Mn |
| Mar 31, 2025 | -21.48 Mn |
| Dec 31, 2024 | -20.67 Mn |
| Sep 30, 2024 | -20.52 Mn |
| Jun 30, 2024 | -16.66 Mn |
| Mar 31, 2024 | -14.35 Mn |
| Dec 31, 2023 | -18.15 Mn |
| Sep 30, 2023 | -10.95 Mn |